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Abstract
Herbal medicine is one of the forms of traditional medical practice. Traditional Chinese medicine
(TCM) and traditional Vietnamese medicine (TVM) are well-known for their long-standing tradition
of herbal medicine.
Secreted by many species of blister beetle, most notably by the 'Spanish fly' (Lytta vesicatoria),
cantharidin inhibits protein phosphatases 1 and 2A (PP1, PP2A). Blister beetle has been used in
Asian traditional medicine to treat Molluscum contagiosum virus (MCV) infections and associated
warts, and is now also used for cancer treatment. A combination of both genomic and postgenomic
techniques was used in our studies to identify candidate genes affecting sensitivity or resistance to
cantharidin. Cantharidin was not found to be related to multidrug resistance phenotype, suggesting
its potential usefulness for the treatment of refractory tumors. Oxidative stress response genes
diminish the activity of cantharidin by inducing DNA strand breaks which may be subject to base
excision repair and induce apoptosis in a p53- and Bcl2-dependent manner.
Cantharidin is one of many natural products used in traditional Chinese medicine and traditional
Vietnamese medicine for cancer treatment. Combined methods of pharmaceutical biology and
molecular biology can help elucidate modes of action of these natural products.
Background
Herbal medicine represents a traditional form of medical
practice in human history. Current ethnobotany and eth-
nopharmacology focus on the systematic exploration of
medicinal herbs among folk medicines [1].
Half a century after the launch of chemotherapy for tumor
treatment [2], anti-neoplastic drugs is now indispensable
for treating hematopoietic malignancies. The concept of
combination therapy in oncology is based on the notion
that leukemia cells resistant to one drug may be suscepti-
ble to other drugs. Clinically, the success of combination
treatments can be hampered by the development of
broad-spectrum or multidrug resistance (MDR). Two
strategies to cope with this problem are to modulate
multidrug resistance by inhibitors of MDR-conferring
proteins [3] or to develop new anticancer drugs without
involvement in MDR phenotypes. Enormous efforts have
been spent to develop such as resistance modulation to
improve treatment for leukemia, but resistance modula-
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tors still frequently show intolerable high toxicity [4]. Nat-
ural products provide a rich source for developing novel
drugs with anti-leukemia activities. The Natural Products
Branch of the National Cancer Institute (USA) has col-
lected and tested over 100,000 natural extracts of plants
and invertebrates [5]. The vast experience of traditional
medicines (e.g., TCM) may facilitate the identification of
novel active substances. This approach has been success-
ful. Camptothecin from Camptotheca acuminata represents
only one outstanding example for such compounds
derived from TCM [6]. Considering the severe limitations
of current cancer chemotherapy, it would be desirable to
have novel drugs which are active against otherwise resist-
ant tumor cells.
In 1996, we started a research program on the molecular
pharmacology and pharmacogenomics of the natural
products derived from TCM [7]. This project became fruit-
ful for the identification and characterization of com-
pounds with anti-tumor and anti-viral activities. Apart
from artemisinin and its prominent semi-synthetic deriv-
ative artesunate which are both approved drugs [8,9], we
have analyzed cellular and molecular mechanisms of sev-
eral other chemically characterized natural products
derived from TCM, e.g., arsenic trioxide, ascaridol, berber-
ine, cantharidin, cephalotaxine, curcumin, homohar-
ringtonine, luteolin, isoscopoletin, scopoletin and others
[10-30]. Furthermore, several novel bioactive com-
pounds, namely tetracentronsine A, tetracentronside A, B
and C, the two novel α-tetralone derivatives, berchemia-
side A and B, and the novel flavonoid quercetin-3-O-(2-
acetyl-α-L-arabinofuranosid), were described and ana-
lyzed in our investigations, [31-33]. Artemisinin displays
a marked anti-malarial activity [34]. Various derivatives
(artesunate, artemether, arteether, artelinate) have been
synthesized to improve this anti-malarial activity.
In 2002, we began a study on the antiviral effects of artesu-
nate. We demonstrated for the first time that artesunate
inhibits NF-κB activity, leading to the inhibition of viral
replication. NF-κB is involved in the transcriptional regu-
lation of early and late proteins of human cytomegalovi-
rus (HCMV) necessary for viral replication [35].
Artesunate also acts against cytomegaloviruses in vivo [36].
We also showed that the antiviral activity of artesunate is
not limited to HCMV. Herpes simplex virus 1, hepatitis B
and C viruses and others can also be inhibited by artem-
isinin and artesunate [35,37,38].
TCM is well-known for its unique diagnosis and treatment
system, whereas other traditional medicines in Asia, such
as TVM, have not gained the same acceptance in medical
practice. Profoundly influenced by TCM, TVM exhibits its
uniqueness via an influence from indigenous medicine of
southern Vietnam. Detailed surveys of TVM and TCM can
be found in recent publications [39-41].
Cantharidin
Screening of extracts
A major problem in conventional cancer chemotherapy is
the severe side-effects on normal tissues prevent treatment
with doses sufficient to kill all cancer cells, which in turn
fosters the development of drug resistance. There is an
urgent need to develop new drugs with improved resist-
ance modulation for tumor therapy. It is the current situ-
ation in cancer chemotherapy in Western medicine that
prompted us to study TCM and TVM. We have been
searching for natural products from medicinal plants with
activity against cancer cells.
In this study, we focused on medicinal plants and animals
used in Vietnam. They were bought by of the authors at
medicinal markets in Ho Chi Minh City, Vietnam (Figure
1). The criteria for medicinal plants and animals to be
included in this study were their traditional use to treat
cancer. The material was further processed by extraction
with solvents of different polarity (petroleum ether, n-
hexane, methanol, chloroform, ethyl acetate, or water).
Extracts with organic solvents were made in a Soxhlet
apparatus, while water extracts were made as decoctions
imitating the original medicinal use. The aim of this
approach was to divide plant constituents into fractions of
different polarity upon extraction.
Only two out of the 27 extracts, namely from Curcuma
longa  and blister beetle ('Spanish fly', Lytta vesicatoria),
reduced cell growth of human CCRF-CEM leukemia cells
to below 20% of untreated controls (Figure 1). We further
tested curcumin and cantharidin, the active ingredients of
Curcuma longa and of Lytta vesicatoria, respectively [16].
Multidrug resistance
Parental CCRF-CEM leukemia cells and their multidrug-
resistant sub-lines CEM/ADR5000, CEM/VLB100, and
CEM/E1000 were used to investigate whether these two
substances are able to inhibit tumor cell growth and to
analyze the involvement of these compounds in multid-
rug resistance (MDR) phenotype. CEM/ADR5000 and
CEMJ/VLB100 are characterized by over-expression of the
MDR-mediating ATP-binding cassette (ABC) transporter
P-glycoprotein (MDR1, ABCB1), while CEM/E1000 over-
expresses the multidrug-resistance related protein 1
(MRP1, ABCC1) [42-44]. Cantharidin is more active than
curcumin and no cross-resistance was observed in multid-
rug-resistant cell lines indicating that both drugs are not
involved in the MDR phenotype (Table 1). Since canthari-
din was active at lower concentrations compared to curcu-
min, we focused our efforts on cantharidin. An overviewChinese Medicine 2007, 2:8 http://www.cmjournal.org/content/2/1/8
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on the chemotherapeutic features of curcumin can be
found in a recent publication [45].
Use of canthardin in Asian and Western medicine
Topical application of cantharidin has a long tradition in
Asian medicine for the treatment of warts caused by Mol-
luscum contagiosum virus (MCV) infections [46], while the
use of cantharidin to treat pediatric MCV infections in
Western academic medicine has been found effective
[47,48]. Blister beetles and cantharidin are also used in
China and Vietnam to treat cancer [49]. Despite its useful-
ness, the potential poisonous effects of cantharidin would
have fatal consequences in the event of careless mistakes
in the use of this compound [50,51]. Not only is exact
dosage is required for the use of cantharidin itself, but also
for raw preparations of blister beetles to be used in tradi-
tional medicines. Cantharidin content varies among indi-
vidual blister beetles as well as among different species.
Blister beetles belong to the order Coleoptera which com-
prises approximately 1500 species.
In this review, our data are compared with well-known
results regarding the molecular and cellular mechanisms
of cantharidin in cancer cells.
Pharmacogenomics of cantharidin
Cantharidin and norcantharidin (a demethylated can-
tharidin derivative, which also has clinical potential) are
protein phosphatase 1 (PP1) and protein phosphatase 2A
(PP2A) inhibitors [52-59]. This activity appears necessary
for the growth inhibition activity of these compounds
[57]. Protein phosphatases are involved, among others, in
the regulation of multiple cellular processes including
apoptosis, signal transduction pathways, cell cycle pro-
Medicinal plants and animals used in Vietnamese medicine and cytotoxicity of hexane, water or methanol extracts (10 μg/ml) to  CCRF-CEM leukemia cells Figure 1
Medicinal plants and animals used in Vietnamese medicine and cytotoxicity of hexane, water or methanol extracts (10 μg/ml) to 
CCRF-CEM leukemia cells. (1) Lytta vesicatoria (whole beetles), (2) Pueralia lobata (roots), (3) Momordica charantia (roots, 
branches), (4) Momordica charantia (fruits), (5) Dichroa febrifuga (roots), (6) Panax ginseng C.A.Mey., (7) Curcuma longa (rhi-
zoma), (8) Trichosanthes kirilowii Maxim (kernels), (9) Glycyrrhiza uralensis (roots). Growth inhibitory activity was measured using 
a growth inhibition assay [16].
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gression, glucose metabolism and calcium transport [60].
Thus, although the biochemical target of cantharidin and
norcantharidin is known, the critical molecular pathways
by which cantharidin and norcantharidin cause growth
inhibition and cell death are unclear [61-63].
In an attempt to identify the molecular determinants that
predict sensitivity or resistance of tumor cells to canthari-
din, we analyzed the microarray database of the National
Cancer Institute (USA). Out of 9706 genes, 21 genes
whose mRNA expression in 60 tumor cell lines correlated
with the highest correlation coefficients to inhibition con-
centration 50% (IC50) values were selected by COMPARE
analysis and false discovery rate calculation [10]. These
genes were subjected to hierarchical cluster analysis to
reveal whether the expression profiles of these genes are
useful to predict sensitivity or resistance of cell lines to
cantharidin. The mRNA expression of the 21 identified
genes were subjected to hierarchical cluster analysis and
cluster image mapping (Figure 2). The resulting dendro-
gram with the genes analyzed on the right can be divided
into three major branches. The dendrogram on the top
shows the cell lines and can also be separated into three
major branches. By generation of a cluster image map
from both dendrograms, areas with different mRNA
expression levels became apparent (Figure 2). The distri-
bution of sensitive or resistant cell lines on the dendro-
gram was significantly different indicating that cellular
response to cantharidin is predictable by these genes [10].
While the specific functions of the proteins encoded by
the 21 identified genes are diverse, it is intriguing that
many of them are in one way or another involved in DNA
damage response, DNA repair, and/or apoptosis [10].
Since cantharidin is an inhibitor of protein phosphatases
1 (PP1) and 2A (PP2A), PPP1R13B, the regulatory subu-
nit 13B of PP1, is particularly interesting. PPP1R13B plays
a central role in the regulation of apoptosis via its interac-
tion with the tumor suppressor gene p53. It regulates p53
by enhancing DNA binding activity and transactivation
function of p53 on the promoters of proapoptotic genes
in vivo [64]. The role of PP1 in the repair of UV-induced
DNA lesions [65] and the induction of cytosine arabino-
side-induced apoptosis have been shown [66]. It is, there-
fore, reasonable to hypothesize that PPP1R13B also has
specific functions in cantharidin-induced DNA repair and
apoptosis. PP1 is one of the four major serine/threonine
protein phosphatases, and new protein phosphatases are
still emerging. They are crucial regulators of many cellular
functions by altering the phosphorylation of target pro-
teins. The level of phosphorylation is a well-controlled
balance by the opposing actions of protein kinases and
protein phosphatases. The PP1 holoenzyme consists of
catalytic and regulatory subunits. Four catalytic (a, b, c, d)
and more than a dozen regulatory subunits have so far
been identified. The regulatory subunits modulate the
substrate specificity and target the holoenzyme to specific
subcellular localizations.
Apoptosis and DNA damage and repair induced 
by cantharidin
The microarray analyses were used to find the genes
responsible for the action of cantharidin. These studies
showed that many apoptosis-related genes and genes
involved in DNA damage and repair correlated with the
IC50 values for cantharidin in the NCI cell line panel. We
analyzed the relevance of apoptosis and DNA damage and
repair induced by cantharidin in more detail. In a recent
study, we reported that cantharidin induces apoptosis by
a p53-dependent mechanism in leukemia cells [24]. Can-
tharidin causes both DNA single- and double-strand
breaks. Colony forming assays with knockout and trans-
fectant cell lines showed that DNA polymerase β con-
ferred increased cell survival after cantharidin treatment,
indicating that base excision repair rather than nucleotide
excision repair is important for cantharidin-induced DNA
lesions. Oxidative-stress resistant thymic lymphoma-
derived WEHI7.2 variants are also more resistant to can-
Table 1: Fifty percent inhibition concentrations (IC50) and relative resistance of curcumin and cantharidin in sensitive and multidrug-
resistant CEM leukemia tumor cell lines [16]
Curcumin Cantharidin
Growth inhibition assay:
CCRF-CEM 30 μM2 0   μM
CEM/ADR5000 28 μM1 7   μM
Relative resistance 0.9 0.9
MTT-Assay:
CCRF-CEM >13.5 μM 1.9 μM
CEM/VBL100 >13.5 μM 1.4 μM
Relative resistance: n.d. 1.4
CEM/E1000 13.5 μM 0.76 μM
Relative resistance n.d. 0.4
n.d.: not determinedChinese Medicine 2007, 2:8 http://www.cmjournal.org/content/2/1/8
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tharidin. These data suggest that cantharidin treatment
causes oxidative stress which damages DNA and triggers
p53-dependent apoptosis.
It has been difficult to determine all critical events respon-
sible for cantharidin-induced cytotoxicity. PP1 and PP2A
which are inhibited by cantharidin [52-59], modulate a
large number of cellular processes by counteracting the
activity of kinases to provide the critical on/off switch for
many pathways [60]. Cell cycle progression is one process
where the increases and decreases of both kinases and
phosphatases are necessary to complete the cycle. Studies
from different laboratories agree that cantharidin and nor-
cantharidin treatment results in a G2/M cell cycle block in
many cell types [68-72]. However, several of these studies
suggest that cell cycle blockade does not cause canthari-
din-induced apoptosis [68-72].
Our data show that cantharidin treatment causes DNA
strand breaks in CCRF-CEM cells [24]. DNA strand breaks
have also been documented in oral cancer KB cells after
norcantharidin treatment [73]. A correlation between an
increase in the mRNA level for several DNA damage repair
genes in the 60 cell line panel and resistance to canthari-
Dendrograms and cluster image map obtained by hierarchical cluster analysis (complete linkage method) of mRNA expression  of 21 genes in 60 NCI cell lines Figure 2
Dendrograms and cluster image map obtained by hierarchical cluster analysis (complete linkage method) of mRNA expression 
of 21 genes in 60 NCI cell lines. The genes are published [10]. The dendrogram on the right shows the clustering of cell lines 
and the dendrogram on the top shows clustering of genes. The cluster image map corresponds to each mRNA expression 
value obtained by microarray analysis. The expression values have been normalized and color-coded as indicated.  The figure is 
taken from [10].
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din argues for DNA damage as a mechanistic component
of cantharidin-induced apoptosis. This is consistent with
the role of p53 in cantharidin-induced apoptosis in this
study because one of the major functions of p53 is to
induce apoptosis when DNA damage exceeds a threshold
[74]. Moreover, p53 plays a role in norcantharidin-
induced apoptosis in glioblastoma cells [68]. Phosphor-
ylation of p53 stabilizes the protein [74,75]; inhibition of
phosphatases may enhance the ability of p53 to exert its
effect. The ability of Bcl-2 to protect against cantharidin-
induced apoptosis seen in this study indicates that DNA
damage-triggered mitochondrial pathway is involved.
Mitochondrial dysfunction and activation of caspases
involved in the intrinsic (mitochondrial) pathway of
apoptosis have also been detected in other cell types after
cantharidin or norcantharidin treatment [69,70,76-83]. A
role of the Fas/CD95 extrinsic pathway of apoptosis has
been reported [84], but not confirmed by other authors
[85].
The cross-resistance of the oxidative stress resistant
WEHI7.2 variants to cantharidin suggests that cantharidin
causes oxidative stress which plays a role in cantharidin-
induced apoptosis. Analogs of cantharidin increase xan-
thine oxidase activity which would increase intracellular
reactive oxygen species (ROS) [86]. It is, therefore, tempt-
ing to speculate that oxidative stress is involved in the
induction of DNA damage by cantharidin. Increase of
endogenous ROS level has repeatedly been shown to
cause significant DNA breakage [87].
Resistance to oxidative stress, increases of Bcl-2, or the
presence of wild type p53 have a modest effect on can-
tharidin-induced toxicity. Mutational inactivation of PolB
but not of ERCC1, key enzymes of base excision repair
and nucleotide excision repair pathways respectively,
exerted an effect on cantharidin cytotoxicity. This suggests
that cantharidin induces non-bulky DNA lesions that are
repaired by base excision repair but not by nucleotide
excision repair. Lesions induced by oxidative stress are
repaired by base excision repair and non-homologous
end joining [88]. This suggests the possibility that multi-
ple mechanisms are responsible for cantharidin-induced
toxicity. In this study, for example, p53 status affected the
IC50 of cantharidin, however, cells with mutated p53 still
died. A p53-independent mechanism of cantharidin-
induced cytotoxicity has been detected in hepatoma cells
[70]. Because cantharidin and norcantharidin inhibit
phosphatases, it would not be surprising that alterations
in multiple pathways are critical for apoptosis. The micro-
array data comparing cantharidin treated and untreated
HL-60 cells suggest that cantharidin affects multiple path-
ways [89]. Given that multiple mechanisms are involved
in cantharidin-induced toxicity, the drug will likely be
most effective against cancer cells with a specific pheno-
type. It is important to test whether this is a cancer cell that
has acquired mutations in DNA repair pathways but
retains wild-type p53 and sensitivity to oxidative stress.
Discussion
Although the potential use of natural products is increas-
ingly recognized in oncology, it has been estimated that so
far only 5000 plant species have been properly studied for
possible medical applications [90]. Considering that there
are 250,000 to 300,000 plant species on this planet, the
majority of this treasure still awaits retrieval.
The isolation of natural products and the elucidation of
their chemical structures enable pharmacological and
molecular biological investigations comparable to those
conducted on chemically synthesized compounds to be
conducted. The identification of target molecules relevant
to diseases allows screening for natural products that are
able to inhibit these targets. This may lay groundwork for
the development of rational treatment of diseases such as
cancer. This kind of research also opens avenues for the
prediction of individual response of a cancer patient to
therapy. We expect that strategies for individualized
tumor therapies will lead to improved results for the
patients. Small molecule inhibitors have the potential to
increase tumor specificity and reduce adverse side effects
on normal tissues. This concept of individualized tumor
therapy is also of great importance for small molecule
inhibitors derived from traditional herbal medicines such
as TCM and TVM. Applying this strategy, we identified
cantharidin as a potential drug candidate. These results
are supported by findings that cantharidin does not cause
myelosuppression in patients [70] and is effective against
cells with a multidrug resistance phenotype [16,91], both
of which are major obstacles of established anti-cancer
drugs. A drawback of cantharidin is its acute toxicity due
to its effect on mucus membranes and the urinary tract
[49,73]. Understanding the mechanism of cantharidin
action will help in the derivation of related compounds
that have reduced toxicity while preserving the anti-tumor
effect [92,93].
Cantharidin's ability to act against multidrug-resistant
cells makes it an ideal compound for individualized can-
cer treatment. If multidrug resistance of a tumor can be
detected by molecular and pharmacological means prior
to standard chemotherapy, the therapy regimen may be
altered and drugs that act against multidrug-resistant
tumors (e.g., cantharidin) may be applied. Such escape
treatment strategies are promising.
Our pharmacogenomic approach points to genes
involved in oxidative stress response, DNA repair and
apoptosis. The generation of hypotheses by genomic tech-
nologies and their verification by molecular biologicalChinese Medicine 2007, 2:8 http://www.cmjournal.org/content/2/1/8
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methods provides an attractive approach. On the other
hand, microarray technologies alone are not sufficient to
elucidate molecular mechanisms of cytotoxic compounds
in cancer cells. Microarray expression profiling can deliver
candidate genes on a transcriptome-wide level. While this
approach is much faster than traditional techniques, not
all associations of genes with the response of tumor cells
to a drug under investigation are of causal relationships
and some may be even unrelated processes. Therefore, we
should only take validated findings seriously.
Conclusion
TCM and TVM are valuable sources for identifying poten-
tial natural products to treat cancer. In the case with can-
tharidin, the use of pharmacogenomic and molecular
biological techniques help elucidate the modes of action
of the natural product. While cantharidin is not involved
in the multidrug resistance phenotype, it induces the gen-
eration of ROS and DNA damage, thereby leading to
apoptosis.
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